BioNexus Gene Lab Cash Conversion
The Cash Conversion Rate (OCF/Net Income) of BioNexus Gene Lab (BGLC) as of Oct 29, 2026 is 61.60 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 139.79 % — a change of -55.94% (lower).
Get this data via API
Financial Data API
Cash Conversion
61.60 %
YoY
-55.94%
Last updated:
The BioNexus Gene Lab Cash Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | Cash Conversion | YoY |
|---|---|---|
| 61.60 % | -55.94% | |
| 139.79 % | +108.71% | |
| 66.98 % | -143.82% | |
| -152.83 % | -12,638.33% | |
| 1.22 % | -97.59% | |
| 50.51 % | -42.70% | |
| 88.15 % | -108.51% | |
| -1,036.06 % | +258.92% | |
| -288.66 % | -388.66% | |
| 100.00 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioNexus Gene Lab Stock analysis
Frequently Asked Questions about BioNexus Gene Lab stock
Cash Conversion Rate (OCF/Net Income) of BioNexus Gene Lab is 61.60 % in 2025.
Cash Conversion Rate (OCF/Net Income) of BioNexus Gene Lab changed from 139.79 % to 61.60 %, representing a -55.94% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.
Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s BioNexus Gene Lab with sector peers and the industry average to assess whether it is attractive.
To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — BioNexus Gene Lab
All Key Metrics — BioNexus Gene Lab
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth